EMD Serono Research & Development Institute, Inc.
PharmaRockland, Massachusetts, USA, United States · Est. 1990
EMD Serono Research & Development Institute, Inc. is a subsidiary of Merck KGaA (Darmstadt, Germany) focused on discovering and developing pharmaceutical treatments in oncology, neurology, and immunology.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
89
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 31
Phase 23
Phase 14
By Therapeutic Area
top 2
Oncology
788%
Immunology
113%
R&D Momentum
56/100
Pipeline Velocity
22/100
Trial Completion Rate
59/100
Pipeline Concentration
78/100
Pipeline Freshness
65/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Active, not recruiting
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Jul 14, 2026
Recruiting
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Jul 3, 2026
Recruiting
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)
Jul 3, 2026
Recruiting
A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
Jul 3, 2026
Recruiting
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)
Jul 1, 2026
Active, not recruiting
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors
Earlier
Jun 30, 2026TrialAn Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Jun 24, 2026TrialAn Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M0324, a Bispecific (MUC-1 x CD40) Antibody as Monotherapy, in Combination With Pembrolizumab, and in Combination With Chemotherapy, in Participants With Selected Advanced Solid Tumors
4 more events
Jun 24, 2026TrialA Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors
Feb 13, 2026TrialAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Jul 21, 2025TrialA Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
May 14, 2025TrialPhase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyNeurologyImmunologyEndocrinology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Oncology
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)